HUP0203914A2 - High order nucleic acid based structures - Google Patents

High order nucleic acid based structures

Info

Publication number
HUP0203914A2
HUP0203914A2 HU0203914A HUP0203914A HUP0203914A2 HU P0203914 A2 HUP0203914 A2 HU P0203914A2 HU 0203914 A HU0203914 A HU 0203914A HU P0203914 A HUP0203914 A HU P0203914A HU P0203914 A2 HUP0203914 A2 HU P0203914A2
Authority
HU
Hungary
Prior art keywords
nucleic acid
high order
acid based
subject
based structures
Prior art date
Application number
HU0203914A
Other languages
English (en)
Hungarian (hu)
Inventor
Frank J Carr
Graham Carter
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9926810.4A external-priority patent/GB9926810D0/en
Priority claimed from GB0011126A external-priority patent/GB0011126D0/en
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HUP0203914A2 publication Critical patent/HUP0203914A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/151—Nucleic acids forming more than 2 strands, e.g. TFOs more than 3 strands, e.g. tetrads, H-DNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/52—Physical structure branched

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HU0203914A 1999-11-13 2000-11-13 High order nucleic acid based structures HUP0203914A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9926810.4A GB9926810D0 (en) 1999-11-13 1999-11-13 High order nucleic acid-based structures
GB0011126A GB0011126D0 (en) 2000-05-10 2000-05-10 High order nucleic acid-based structures
PCT/EP2000/011197 WO2001036624A1 (en) 1999-11-13 2000-11-13 High order nucleic acid based structures

Publications (1)

Publication Number Publication Date
HUP0203914A2 true HUP0203914A2 (en) 2003-03-28

Family

ID=26244234

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203914A HUP0203914A2 (en) 1999-11-13 2000-11-13 High order nucleic acid based structures

Country Status (16)

Country Link
EP (1) EP1228201A1 (zh)
JP (1) JP2003522524A (zh)
KR (1) KR20020059727A (zh)
CN (1) CN1390253A (zh)
AU (1) AU782880B2 (zh)
BR (1) BR0015484A (zh)
CA (1) CA2391084A1 (zh)
CZ (1) CZ20021472A3 (zh)
HK (1) HK1052529A1 (zh)
HU (1) HUP0203914A2 (zh)
MX (1) MXPA02004727A (zh)
NO (1) NO20022231L (zh)
PL (1) PL358811A1 (zh)
RU (1) RU2002113755A (zh)
SK (1) SK6042002A3 (zh)
WO (1) WO2001036624A1 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
JP5033303B2 (ja) 2001-07-05 2012-09-26 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
CA2849072A1 (en) * 2011-08-05 2013-02-14 President And Fellows Of Harvard College Compositions and methods relating to nucleic acid nano-and micro-technology
CN104781416B (zh) 2012-07-24 2017-07-04 哈佛学院院长及董事 核酸纳米结构的自装配
WO2014074597A1 (en) 2012-11-06 2014-05-15 President And Fellows Of Harvard College Compositions and methods relating to complex nucleic acid nanostructures
JP2017505104A (ja) * 2013-11-08 2017-02-16 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド インビボにおける薬剤送達のための核酸ナノ構造体
TWI621584B (zh) 2014-05-22 2018-04-21 哈佛大學校長及研究員協會 可縮放核酸奈米製造技術
EP3967651A1 (en) 2016-03-11 2022-03-16 Children's Medical Center Corporation Nucleic acid nanoswitch catenanes
US11254972B2 (en) 2016-08-02 2022-02-22 President And Fellows Of Harvard College Crisscross cooperative self-assembly
JP7267416B2 (ja) * 2018-07-12 2023-05-01 百薬智達（北京）納米生物技術有限公司 核酸ナノ粒子、それを含む薬学的組成物、アドリアマイシン含有薬物及びその製造方法
CN110711254B (zh) * 2018-07-12 2022-07-26 百药智达（北京）纳米生物技术有限公司 核酸纳米颗粒及包含其的药物组合物
CN110960536B (zh) * 2018-09-30 2022-07-26 百药智达（北京）纳米生物技术有限公司 含阿司匹林的药物、其制备方法、药物组合物及应用
CN110960534B (zh) * 2018-09-30 2022-07-26 百药智达（北京）纳米生物技术有限公司 含五氟尿嘧啶的药物、其制备方法、药物组合物及其应用
CN110960690B (zh) * 2018-09-30 2022-07-22 百药智达（北京）纳米生物技术有限公司 含表柔比星的药物、其制备方法、药物组合物及其应用
CN110960530B (zh) * 2018-09-30 2022-07-22 百药智达（北京）纳米生物技术有限公司 含他克林的药物、其制备方法、药物组合物及其应用
CN110960542B (zh) * 2018-09-30 2022-07-26 百药智达（北京）纳米生物技术有限公司 含吡柔比星的药物、其制备方法、药物组合物及其应用
CN111053765B (zh) * 2018-10-16 2022-07-26 百药智达（北京）纳米生物技术有限公司 含紫杉醇的药物、其制备方法、药物组合物及应用
CN111068065B (zh) * 2018-10-22 2022-07-26 百药智达（北京）纳米生物技术有限公司 含奥沙利铂的药物、其制备方法、药物组合物及其应用
CN111084887B (zh) * 2018-10-23 2022-07-22 百药智达（北京）纳米生物技术有限公司 含黄酮的药物、其制备方法、药物组合物及应用
CN111096965B (zh) * 2018-10-29 2022-07-26 百药智达（北京）纳米生物技术有限公司 含双氢青蒿素的药物、其制备方法、药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0151631A1 (en) * 1983-08-03 1985-08-21 The Research Foundation Of State University Of New York Nucleic acid branched junctions with precisely defined migrational mobility
US5386020A (en) * 1991-01-10 1995-01-31 New York University Multiply connected, three-dimensional nucleic acid structures
US5278051A (en) * 1991-12-12 1994-01-11 New York University Construction of geometrical objects from polynucleotides
US6072044A (en) * 1996-04-26 2000-06-06 New York University Nanoconstructions of geometrical objects and lattices from antiparallel nucleic acid double crossover molecules

Also Published As

Publication number Publication date
EP1228201A1 (en) 2002-08-07
BR0015484A (pt) 2002-07-02
NO20022231D0 (no) 2002-05-10
CA2391084A1 (en) 2001-05-25
HK1052529A1 (zh) 2003-09-19
AU782880B2 (en) 2005-09-08
MXPA02004727A (es) 2002-08-30
AU2000101A (en) 2001-05-30
PL358811A1 (en) 2004-08-23
RU2002113755A (ru) 2004-01-10
NO20022231L (no) 2002-05-10
KR20020059727A (ko) 2002-07-13
WO2001036624A1 (en) 2001-05-25
CZ20021472A3 (cs) 2002-07-17
SK6042002A3 (en) 2002-12-03
JP2003522524A (ja) 2003-07-29
CN1390253A (zh) 2003-01-08

Similar Documents

Publication Publication Date Title
HUP0203914A2 (en) High order nucleic acid based structures
DK1870417T3 (da) Peptidacceptor-ligeringsmetoder
WO2004048526A3 (en) MODULATION OF HIF1α AND HIF2α EXPRESSION
EA200401398A1 (ru) Замещённые фенилацетамиды и их применение в качестве активаторов глюкокиназы
DE60232653D1 (de) Pharmazeutisch wirksame uridinester
DE60310944D1 (de) Weitere neue formen von interferierende rns moleküle
EP2284267A3 (en) Modulation of diacylglycerol acyltransferase 2 expression
BRPI0520369A2 (pt) catalisador orgánico com compatibilidade intensificada de enzima
WO2005000201A3 (en) Modulation of apolipoprotein (a) expression
AR024944A1 (es) Amidas de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y su preparacion
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
BR9508308A (pt) Derivados de benzoíla e sintese dos mesmos
DE602005020185D1 (de) Verfahren zur herstellung von 17-hydroxy-6 beta, 7 beta, 15 beta,16 beta-bismethylen-17alpha-pregn-4henprodukte für dieses verfahren
WO2004055162A3 (en) Modulation of endothelial lipase expression
BR9908215A (pt) Derivados de ácidos hidroxâmico e carboxìlico
DK1594885T3 (da) Lægemiddel til vækstinhibering af tumorer
SE9804212D0 (sv) Compounds
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
WO2004052309A3 (en) Modulation of stat 6 expression
WO2005021727A3 (en) Isoform-specific targeting of splice variants
CY1111004T1 (el) Χρησιμες συνθεσεις για τη ρυθμιση της δρασης του γονιδιου της παρκινης
ATE256701T1 (de) Mit phosphonsäureester-, phosphonsäure- oder carbaboran-funktionen substituierte oligomere und die entsprechenden pna-monomere
Mehlführer et al. Stereospecific Synthesis of (2 S, 4 S, 6 S)-2-Amino-4, 6-Dihydroxypimelic Acid
AU2003276872A1 (en) Methods for identifying antimicrobial compounds
WO2004048524A3 (en) Modulation of stat2 expression

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees